Kymab to attack Regeneron’s mice experiments in human rat patent case
UK biopharmaceutical company Kymab may attack experiments done by US biotechnology giant Regeneron creating genetically modified mice with splices of human genomes, as it defends its proposed patent for a human rat.
For information on rights and reprints, contact subscriptions@lawyerly.com.au
